Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Febuxostat versus allopurinol for cardiovascular surrogate risk reduction in gout
NL-OMON43921Phase 4Active, not recruiting
- Sponsor
- Menarini Group
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in gout and hyperuricemia comparing Febuxostat with Allopurinol (2 arms). Primary endpoint: Change in pulse wave velocity. Started Nov 2015; status: active, not recruiting.
02
Drugs
febuxostatallopurinol
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NL-OMON43921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43921.